This month, US magistrate judge Richard A. Lloret granted Boehringer Ingelheim (BI)’s motion to compel AbbVie to produce prelitigation disclosures and settlements concerning its brand-name adalimumab, Humira.
This month, US magistrate judge Richard A. Lloret granted Boehringer Ingelheim (BI)’s motion to compel AbbVie to produce prelitigation disclosures as well as settlements concerning its brand-name adalimumab, Humira.
BI is engaged in a lawsuit with AbbVie over biosimilar adalimumab, Cyltezo, and the biosimilar developer had requested that the court require AbbVie to produce relevant information from another such litigation, concerning Amgen’s Amgevita, as well as from settlement agreements that AbbVie entered into with Amgen, Samsung Bioepis, and Mylan regarding their biosimilar adalimumab products.
Judge Lloret found that the disclosures concerning the litigation with Amgen are relevant to the case and can be provided by AbbVie with minimal burden, as long as reasonable confidentiality procedures are followed. He also found that the disclosures related to settlements are likely to be relevant to BI’s defenses of patent invalidity and unenforceability and that, given adequate confidentiality provisions, producing settlement documents does not pose an undue burden for AbbVie.
Separately, Judge Lloret denied AbbVie’s motion to require that BI provide more complete responses to 2 of its questions, one related to BI’s safe harbor defense and the other related to the time at which BI learned about patents that are at issue in the suit.
In the first instance, found Judge Lloret, the probative value of the information sought by AbbVie is “remote” and unlikely to be material to the resolution of the case’s issues. In the second, he found that the burden imposed by the discovery is disproportionate to whatever value it may have to the resolution of the case.
These new developments follow Judge Lloret’s February 2019 order to BI to divulge its launch plans for Cyltezo as part of the patent dispute. According to a memorandum, BI’s plans, and the degree to which AbbVie’s alleged patent thicket for Humira may have delayed those launch plans, may have a legitimate impact on BI’s unclean hands defense: a legal defense that bars a party who is asking for a judgment from receiving the court’s help if that party has behaved unethically with respect to the subject of the lawsuit.
According to BI, AbbVie’s strategy of acquiring what BI describes as overlapping, noninventive patents to hinder biosimilar competition could constitute unclean hands on AbbVie’s part.
Also in February, Judge Lloret ordered AbbVie to turn over 14 different categories of documents, including those related to its patenting program and its efforts directed toward mitigating the impact of biosimilar competition on its business.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.